Kimia Therapeutics Raises $55 Million Series A
BERKELEY, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Kimia Therapeutics, Inc. (Kimia), a biotechnology company generating a chemical atlas for treating human disease, today announced that it has closed a $55 million Series A financing. The Column Group and Dimension led the Series A round and was joined by Horizons Ventures and individual investors. The funding will enable Kimia to expand its ATLAS platform and pursue a broad range of therapeutic targets in oncology, immunology and inflammation while continuing to partner with Carmot Therapeutics Inc. (Carmot) on key metabolic programs.
- – Kimia is advancing its ATLAS platform that combines high-throughput chemistry with chemical biology, genome editing and machine learning to create a chemical map of the druggable proteome and accelerate the discovery of novel therapeutics targets and drug leads –
BERKELEY, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Kimia Therapeutics, Inc. (Kimia), a biotechnology company generating a chemical atlas for treating human disease, today announced that it has closed a $55 million Series A financing. - The Column Group and Dimension led the Series A round and was joined by Horizons Ventures and individual investors.
- Kimia is building a next generation therapeutics discovery platform called ATLAS that combines AcTive Learning with Automated Synthesis and screening.
- ATLAS is powered by a high-throughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds.